Posted by Michael Wonder on 11 Jun 2020
US FDA approves updated Novartis Beovu label to include additional safety information
11 June 2020 - Novartis worked with US FDA to update Beovu (brolucizumab) prescribing information to guide healthcare professionals in their treatment of patients with wet AMD.
Novartis announced today that the US FDA has approved a label update for Beovu (brolucizumab) to include additional safety information regarding retinal vasculitis and retinal vascular occlusion.
This approval follows Novartis’ announcement that it would pursue worldwide label updates after a review and further characterization of rare post-marketing safety events reported to Novartis.
